Disclosure of Adolescent Substance Use in Primary Care: Comparison of Routine Clinical Screening and Anonymous Research Interviews

The American Academy of Pediatrics recommends substance use screening in adolescent primary care. Many studies of substance use prevalence and screening tool validation are conducted under research protocols that differ from routine clinical screening in context, consequences, and privacy implicatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of adolescent health 2019-04, Vol.64 (4), p.541-543
Hauptverfasser: Gryczynski, Jan, Mitchell, Shannon G., Schwartz, Robert P., Kelly, Sharon M., Dušek, Kristi, Monico, Laura, O'Grady, Kevin E., Brown, Barry S., Oros, Marla, Hosler, Colleen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The American Academy of Pediatrics recommends substance use screening in adolescent primary care. Many studies of substance use prevalence and screening tool validation are conducted under research protocols that differ from routine clinical screening in context, consequences, and privacy implications. This study is a secondary analysis drawing from two projects focused on adolescent primary care patients, aged 12–17, conducted nearly contemporaneously in a Federally Qualified Health Center system. The first project conducted anonymous research interviews with patients (N = 525), while the other tracked routine clinical screening as part of a larger service implementation project (N = 5,971). Both projects assessed substance use with the CRAFFT screening tool. Rates of substance use disclosure and substance use problems were over three and four times higher, respectively, in the anonymous research interview sample compared to rates found in routine clinical screening (p values < .001). Routine clinical screening may underestimate substance use among adolescents.
ISSN:1054-139X
1879-1972
DOI:10.1016/j.jadohealth.2018.10.009